valu usd unless otherwis note
pharma excel devic consum
segment head right direct
ytd perform devic consum also
notabl provid good visibl consequ believ
abl overcom potenti zytiga gener competit
achiev mid-single-digit oper revenu growth mid- high-
single-digit ep growth upsid guidanc possibl
take estim high end guidanc increas
ww revenu estim guidanc new
estim organ guidanc
guidanc exclud fx new revenu estim
higher prior estim strength wit
jnj pharmaceut segment past quarter especi
intern suggest upsid new estim still occur
increas revenu estim ep
new estim adjust divestitur
lifescan advanc steril product expect close earli
ww total compani revenu estim impli oper
growth impress consid sale eros sever brand
due generic/biosimilar competit remicad zytiga procrit
concerta tracleer exclud zytiga equat
revenu estim impli cc revenu growth
double-digit growth intern pharmaceut segment
continu intern pharmaceut revenu increas
cc growth
oncolog immunolog stood estim least
cc intern pharmaceut revenu growth
result despit gener competit zytiga believ ww
pharmaceut revenu growth reach mid-single-digit
new drug launch esketamin europ erleada europ
erdafitnib contribut pharma growth
recoveri medic devic consum segment posit
indic improv segment year-to-d
in-lin manag commentari share may busi
review devic intervent solut vision advanc
surgeri continu well spine declin less may return
growth consum new product launch oral
babi share gain over-the-counter give us confid
segment may final turn around
initi estim rais price target estim
y/i forecast mid-single-digit pharma
growth growth devices/consum new target old
base sum part analysi assign premium
valuat pharma discount devic versu peer
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
arriv price target use sum-of-the-
part sotp price-to-earnings analysi valu three segment
medic devic consum separ
base peer group multipl base case estim
assum mid-single-digit oper growth
margin expans share buyback price target
impli price-to-earnings multipl ep estim
 lift revenu growth basi point
restructur portfolio ration lead
superior oper leverag rel base case scenario
pharmaceut price rhetor lead legisl
chang govern negoti price
multipl ep estim y/i
assumpt
aggress eros remicad zytiga
brand biosimilar gener competit lack
 depress revenu growth neg
downward pressur multipl downsid
scenario impli price-to-earnings multipl y/i
ep estim assumpt
forecast organ revenu growth
oper growth bp higher organ revenu
growth higher last year despit greater
remicad sale eros tougher year-over-year comp
expect organ growth high-single-digit
pharmaceut segment includ high-teen declin
remicad gener competit zytiga
start novemb
mega-blockbust
contribut new product main growth
driver segment mega-blockbust
 brand ww annual peak sale potenti
billion stelara imbruvica darzalex xarelto
invega sustenna/trinza estim ww
sale five brand increas year-over-year
exclud currenc estim ww sale
mega-blockbust increas high-teen led
stelara imbruvica darzalex new brand tremfya
erleada contribut billion
pharmaceut pipelin enough late-stag compound
produc steadi flow new drug nme
esketamin erdafitinib submit approv
year market esketamin
studi treatment-resist depress
major depress disord patient risk suicid
ideat erdafitinib expand jnj oncolog portfolio solid
set goal grow faster market medic
devic end-market annual growth
rate around certain end-market vision
electrophysiolog advanc surgeri grow
line market compens slower-growth
orthoped categori new product launch
year qualiti improv adapt
busi model chang environ
element strategi achiev goal
vision clear strategi extend leadership
contact lens forecast segment within vision
contact lens surgic grow compound-annual-growth-rate
plan launch new product year
contact lens among first
transit contact lens expect launch next year
integr abbott medic optic span countri
complet disrupt custom
exhibit estim vs report result
exhibit contribut variou segment revenu growth
varianc tableactualrbc estimateconsensu except ep fy gross sg oper interest expens pre-tax tax wwww revenu brand growth ww excl revenu medic suppli devic
exhibit segment estim report result ww
exhibit intern pharmaceut segment estim report result
exhibit pharmaceut segment ww revenu organ growth rate therapeut
categori geographi
sale ww ww pharma excl ww ww pharma excl ww ww pharma excl ww ww pharma excl diseas ww ww pharma excl ww ww pharma ww excl growth medic suppli devic
exhibit medic devic estim report result ww revenu
exhibit ww revenu organ growth rate variou categori within devic
geographi
medcial devic segment ww includ fxy/i y/i product ww ww devic excl ww ww devic excl ww ww devic excl ww ww devic excl fx diabet ww ww devic excl ww excl growth medic suppli devic
exhibit consum estim report result ww revenu
exhibit ww revenu organ growth rate variou categori within consum
geographi
consum segment ww includ fxmedcial devic segment ww includ fxy/i y/i product ww ww consum excl ww ww consum excl ww ww consum excl ww ww consum excl ww ww consum excl ww consum excl ww excl growth medic suppli devic
segmentsp/ estimate ep contributioncontribut price targetconsum million except ep targetupsid scenariodownsidetot interest expens share dilut medic suppli devic
price target base sum-of-the-part sotp analysi target price-to-earnings
multipl base year medic devic consum segment
respect correspond peer group multipl
assign premium multipl segment superior
underli growth outlook compar peer pharmaceut segment contribut
toward price target medic devic consum price target impli
blend price-to-earnings multipl ep estim y/i discount
price-to-earnings ntm averag basi outperform rate share
risk rate price target
face risk typic global diversifi healthcar compani includ
slump navig fda may risk price target rate
johnson johnson one largest diversifi healthcar busi
world oper compani encompass broad rang product across
healthcar field compani world-wide busi divid three main segment
medic devic diagnost sale consum
